Skip to main content

CCTG Connection



Published:
Category: Publications
Publications: General Review
Effects of cannabinoids on immune checkpoint inhibitor response: CCTG pooled analysis
 
Immune checkpoint inhibitors (ICI) have become an important treatment option for cancer patients and has been associated with improved survival outcomes across various tumor types. Cannabinoids are active components of cannabis and include tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabis use has increased in Canadian cancer patients and is often used for symptom management.
Read More

Published:
Category: Trials
Closed to accrual: MAC27

MAC27 - COMPASSHER2 residual disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and Tucatinib has closed to accrual.

Read More

Published:
Category: Trials
Trial closure: IND232

IND.232, a Phase II Study of Durvalumab (MEDI4736) with or without tremelimumab in patients with metastatic castration resistant prostate cancer, has permanently closed.

Read More



Published:
Category: Group updates
Judy Needham, Chair Emeritus, Patient Representative Committee

It was an honour to recognize Judy Needham with the Excellence in Clinical Trials Conduct – Patient Engagement award for her unwavering commitment to patient engagement at CCTG. Judy joined CCTG as a Patient Representative in May 2012 on the Breast Site Committee and became the Chair, CCTG Patient Representatives Committee, in 2014, she successfully led the PRC for over 10 years stepping down this year. 

Read More

Published:
Category: Group updates
Dr. Moira Rushton Ottawa Hospital Research Institute

Congratulations to Dr. Moira Rushton, a Medical Oncologist from the Ottawa Hospital Research Institute who has been awarded the Elizabeth Eisenhauer Early Drug Development Young Investigator Award for her work on CCTG IND trials and committees.

I am truly honored to have been selected as the recipient of this year’s Elizabeth Eisenhauer early drug development young investigator award.  My time at CCTG was an invaluable formative experience and continues to meaningfully impact my clinical practice and academic career,” says Dr Rushton.

Read More

Published:
Category: Group updates
PR.24 Team Odette Cancer Centre at Sunnybrook Health Sciences Centre

Congratulations to the PR.24 trial team from Odette Cancer Centre who were presented the Phase III Program Team Award at the 2025 Spring Meeting for their work and dedication to this CCTG led prostate cancer trial. This recognition is awarded to a non-MD team of clinical research associates, nurses, pharmacists and others who participated in this phase III clinical trial to acknowledge their efforts and dedication to the success of clinical trials.

Read More

Published:
Category: Group updates
Iryna Sokolenko - North York General Hospital

CCTG was pleased to present the Excellence in Clinical Trials Conduct award to Iryna Sokolenko at North York General Hospital for her work to support our trials and contributions to patient-focused research. Iryna is the PCRA for CRC.10 and has been recognized as having exceptional attention to detail who's genuine care made participating in the trial a positive experience for patients. This is presented annually to an individual who exemplifies excellence in clinical trial operations and compliance at their institution.

Read More

Published:
Category: Group updates
Dr. Rebecca Wong Princess Margaret Cancer Centre

We are honoured to announce that the 2025 Joseph Pater Founder’s Award for Excellence in Clinical Trials Research has been presented to Dr. Rebecca Wong Princess Margaret Cancer Centre for her many years of trial and committee leadership with the group.She was Chair of CCTG’s Symptom Control (now Supportive Care) Committee from 2001-2018, and Esophageal disease-oriented group from 2009-2018.  She is currently a member of CCTG’s Clinical Trials Committee.

Read More